Kiora Pharmaceuticals Inc. (KPRX) intrinsic value & 10-year financials
Kiora Pharmaceuticals Inc. (KPRX) has a Graham intrinsic value of $28.90 per share. At $2.40 on Oct 17, 2026, the stock trades 92% below that value. Over the last 10 fiscal years revenue grew 48.7% a year to $0, with an average return on invested capital of 337.4%.
- Graham intrinsic value
- $28.90
- Share price (Oct 17, 2026)
- $2.40
- Price vs Graham value
- 92% below
- Market cap
- $9.8M
- Revenue (FY2025)
- $0
- Revenue growth (10-yr CAGR)
- 48.7%
- ROIC (10-yr avg)
- 337.4%
- Free cash flow (FY2025)
- -$10.1M
KPRX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $0 | -$10.8M | -$2.64 | -$10.1M | — | -77.4% |
| FY2024 | $16.0M | $3.6M | $0.87 | $8.6M | 28.2% | 22.3% |
| FY2023 | $0 | -$12.5M | -$2.69 | — | — | -274.9% |
| FY2022 | — | -$13.6M | -$18.55 | — | — | -353.7% |
| FY2021 | $0 | -$16.4M | -$1.77 | -$11.0M | — | -426.5% |
| FY2020 | $12.1K | -$8.1M | -$0.89 | -$7.3M | -68104.8% | -178.8% |
| FY2019 | $2.7M | -$7.1M | — | — | — | -249.4% |
| FY2018 | $1.7M | -$10.8M | — | -$10.9M | -656.3% | -309.4% |
| FY2017 | $407.5K | -$13.2M | — | -$6.5M | — | 1171.6% |
| FY2016 | $669.3K | -$13.3M | — | — | — | 4050.6% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
KIORA PHARMACEUTICALS INC revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
KIORA PHARMACEUTICALS INC has historically struggled to out-earn its cost of capital, averaging just -10.0% ROIC.
KIORA PHARMACEUTICALS INC capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, KIORA PHARMACEUTICALS INC is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $28.90 per share.